Industry news that matters to you.  Learn more

PROOF Centre Collaboration Focuses on Prognostic Biomarkers for Chronic Kidney Disease

The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) recently announced a new partnership with AstraZeneca and the Canadian Study of Prediction of Death, Dialysis and Interim Cardiovascular Events (CanPREDDICT) to develop a blood test to predict the rate of disease progression in patients with chronic kidney disease (CKD).

TGen Method Isolates Biospecimens for Treatment of Kidney Disease

Researchers at the Translational Genomics Research Institute (TGen) have developed a method of isolating biospecimens that could lead to a less costly, less invasive and more accurate way of diagnosing chronic kidney disease, or CKD.

Evotec and Harvard University Expand Strategic Alliance into Kidney Disease

Evotec AG recently announced a second strategic alliance with Harvard University, this time including Brigham and Women’s Hospital aimed at discovering and developing new biomarkers and treatments in the field of kidney disease. The first successful collaboration ‘CureBeta’ was established in March 2011 to develop new diabetes therapies targeting beta cell regeneration.

Triple-Biomarker Approach Improves Chronic Kidney Disease Prediction Accuracy

Researchers have found that a combination biomarker approach improves risk prediction for chronic kidney disease (CKD). The study, published in the Journal of the American Medical Association (JAMA), concluded that adding cystatin C to the combination of creatinine and albumin-to-creatinine ratio (ACR) measures improved the predictive accuracy for all-cause mortality and end-stage renal disease.